Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents

DOI10.1002/BIMJ.201700166zbMath1419.62373arXiv1709.00918OpenAlexW2751316271WikidataQ64957294 ScholiaQ64957294MaRDI QIDQ4967095

J. L. Jiménez, Mourad Tighiouart, Mauro Gasparini

Publication date: 2 July 2019

Published in: Biometrical Journal (Search for Journal in Brave)

Full work available at URL: https://arxiv.org/abs/1709.00918

zbMATH Keywords

continual reassessment methoddrug combinationcancer phase I trialsattributable toxicitycopula type models

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Characterization and structure theory for multivariate probability distributions; copulas (62H05)

Related Items (1)

Flexible use of copula‐type model for dose‐finding in drug combination clinical trials

This page was built for publication: Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents